XPO-1 in Combination With RCHOP for DH/TH Lymphoma

Zhejiang Cancer Hospital10 enrolled

Overview

The purpose of this study was to evaluate the efficacy and safety of Selinexor in combination with RCHOP in first-line treatment of patients with DH or TH lymphoma.

This is a prospective, single-arm, single-center clinical study evaluating the first-line treatment of DH or TH lymphoma with Selinexor combined with RCHOP. There are three stages: screening, treatment and follow-up period. The screening period was 28 days before the first dose. Treatment period: Enrolled subjects were treated with Selinexor in combination with RCHOP every 21 days for a maximum of 6 cycles until the efficacy of SD or PD, drug toxicity became intolerable, subject withdrawal of consent, death, or continuation of chemotherapy deemed unsuitable by the investigator. Lugano2014 criteria were used to evaluate the efficacy during treatment. Objective effective rate, safety and survival data were observed during the experiment. After stopping treatment or completing 6 cycles of treatment, subjects entered the follow-up period, during which imaging evaluation (enhanced CT at focal site is recommended) was performed at the following intervals: once every 3 months for 2 years, once every 6 months for 3-5 years, and once every 5 years until the end of the follow-up period.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Double Hit Lymphoma Triple Hit Lymphoma

Interventions

Selinexor+RCHOPDRUG

XPO-1 inhibitor selinexor in combination with RCHOP

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Volunteer to participate in clinical studies 2. Age: 18\~75 (inclusive), male and female. 3. Histopathologically confirmed high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 gene rearrangement. 4. No previous chemotherapy, radiotherapy, immunotherapy or other anti-tumor therapy. 5. ECOG score is 0-2. 6. there must be at least one evaluable or measurable lesion that meets Lugano2014 criteria. 7. Adequate organ and bone marrow function. 8. Left ventricular ejection fraction (LVEF) ≥ 50% in cardiac function examination. 9. Serum pregnancy test negative Exclusion Criteria: 1. Left ventricular ejection fraction (LVEF) ≥ 50% in cardiac function examination. 1) Mixed lymphoma (Hodgkin's lymphoma + non-Hodgkin's lymphoma), or DLBCL transformed from inert non-Hodgkin's lymphoma, or gray zone lymphoma (lymphoma between DLBCL and Hodgkin's lymphoma), or inert lymphoma with MYC, BCL2, BCL6 gene rearrangement. 2. known central nervous system involvement. 3. received prior anti-tumor therapy 4. Is participating in another clinical study or is receiving the first investigational drug less than 4 weeks after the completion of treatment in the previous clinical study 5. Had other malignant tumors in the past 5 years 6. Major surgery was performed within 28 days prior to study initiation 7. Cardiovascular function is unstable 8. Active infection

Locations (1)

Zhejiang Cancer Hospital

Hangzhou, Zhenjiang, China

RECRUITING

Outcomes

Primary Outcomes

Objective Response Rate

CR plus PR

Time frame: From date of first day of treatment until the date of last day of treatment

Secondary Outcomes

PFS

Progression Free Survival

Time frame: From date of first day of treatmentuntil the date of first documented progression, assessed up to 24 months

Overall Survival

Time frame: From date of first day of treatmentuntil the date of first documented date of death from any cause, assessed up to 24 months

AE and SAE

Adverse event and serious adverse event

Time frame: From date of first day of treatmentuntil 30 day after last treatment

Central Contacts

Cong Li

CONTACT

15267115611 licong@zjcc.org.cn

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.